title: Effect of corticotropin-releasing factor-binding protein on prostaglandin release from cultured maternal decidua and on contractile activity of human myometrium in vitro.
abstract: Human placenta and uterine tissues are sites of production and local action of corticotropin-releasing factor (CRF). The recent evidence that CRF-binding protein (CRF-BP), a protein that blocks CRF-induced pituitary ACTH release, is produced by placental tissues suggested the present study to investigate the effects of CRF-BP on prostaglandin release and contractile activity of myometrial strips. Primary cultures of decidual cells were prepared using tissue collected from healthy women undergoing cesarean delivery at term. Mechanical and enzymatic cell dispersions were carried out, and experiments were performed 24-28 h after cell plating. The prostaglandin E2 (PGE2) concentration in cultured medium was measured by RIA. Myometrial strips were obtained from the upper edge of the uterine incision during elective cesarean section at term. Dissected free of connective tissue, strips were mounted in a 30-mL two-chamber organ bath containing oxygenated Tyrode's buffer (37 C) and connected to a two-channel isometric smooth muscle transducer. Cultured decidual cells collected at term significantly increased the release of PGE2 in the presence of CRF (P < 0.01). The addition of CRF-BP did not significantly modify PGE2 release, but completely reversed the effect of CRF. When human myometrial strips were incubated in the presence of CRF and PGF2 alpha, a significant increase in contractile activity was observed (P < 0.01); preincubation with CRF-BP prevented the increased contractile activity induced by CRF. The present data show that CRF-BP is able to counteract the biological effect of CRF on human pregnancy endometrium and myometrium and suggest that CRF-BP may be a regulatory protein that plays a role in the local function of uterine tissues during pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, Universities of Modena, Torino, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Petraglia
authors.forename: C
authors.initials: C
authors.lastname: Benedetto
authors.forename: P
authors.initials: P
authors.lastname: Florio
authors.forename: G
authors.initials: G
authors.lastname: D'Ambrogio
authors.forename: A D
authors.initials: AD
authors.lastname: Genazzani
authors.forename: L
authors.initials: L
authors.lastname: Marozio
authors.forename: W
authors.initials: W
authors.lastname: Vale
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000494:pharmacology*; D002478:Cells, Cultured; D002585:Cesarean Section; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D003656:Decidua / Q000378:metabolism*; D015237:Dinoprost / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009215:Myometrium / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy / Q000502:physiology*; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D002352:Carrier Proteins; D011994:Recombinant Proteins; C067133:corticotropin releasing factor-binding protein; D003346:Corticotropin-Releasing Hormone; D015237:Dinoprost; D015232:Dinoprostone